Oxford Immunotec, has entered into a distribution agreement with RIKEN Genesis in Japan. As per the agreement, RIKEN will have exclusive distribute Oxford’s T-SPOT Discovery SARS-CoV-2 kit. The kit has been developed to detect and measure SARS-CoV-2 specific T cells, thereby offering more insight into immunity responses to the SARS-CoV-2 virus.

Chembio Diagnostics it has received a $12.7m contract from the Biomedical Advanced Research and Development Authority (BARDA), for developing and procuring Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for its rapid, multiplex DPP Respiratory Antigen Panel point-of-care test system. The test is designed to provide simultaneous, discrete, and differential detection of Influenza A, Influenza B and SARS-CoV-2 antigens from a single patient respiratory specimen. It is hoped to assist in the containment of Covid-19 cases during flu season.

TNG Dx has partnered with the US Department of Health and Human Services and eTrueNorth to create a rapid RNA extraction protocol as part of a community-based surveillance initiative. The new methodology will help clinical laboratories to deliver Covid-19 analysis and results faster, thereby affordable increasing the number of tests they can process.

European-based Selfdiagnostics is planning on submitting a request for authorisation on for its at-home molecular diagnostic test to help in the detection of the SARS-CoV-2 virus. Selfdiagnostics rapid PCR is the first multifunctional test that is able to detect Covid-19 and influenza from one nasal swab.